Chosa (XSAT: CHOSA)

Last close As at 13/11/2026

SEK0.54

▲ −0.05 (−8.78%)

Market capitalisation

SEK50m

Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress clinical development of the technology.

Latest Insights

View More

Healthcare | edison tv

CHOSA Oncology – executive interview

Healthcare | Update

Chosa Oncology — Making headway in precision oncology

Healthcare | Update

RhoVac — On the home straight

Share Price Chart

Market Data

Share Price SEK0.54
Market Cap SEK50m
52-Week High SEK1.99
52-Week Low SEK0.41
% Change 1M 0.7
% Change 6M (32.8)
% Change 12M (50.9)
Ave. Daily Volume 1yr 47,852

Sector

Healthcare

Equity Analyst

Key Management

  • Claus Frisenberg Pedersen

    CFO

  • Neil Goldsmith

    Chairman

  • Peter Buhl Jensen

    CEO

Update

Healthcare

RhoVac — Funded to execute Phase IIb study as planned

Initiation

Healthcare

RhoVac — Stopping metastasis in its tracks